Search results
Novartis to buy Mariana Oncology in radiopharmaceutical expansion
BioPharma Dive via Yahoo Finance· 20 hours agoThis story was originally published on BioPharma Dive. To receive daily news and insights, subscribe...
Morphosys says Novartis takeover progressing as planned for H1 2024
WHTC 1450 Holland· 4 days agoBERLIN (Reuters) - Morphosys said its takeover by Novartis was still expected to be closed in the...
Mather Group LLC. Acquires 1,712 Shares of Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 2 days agoMather Group LLC. boosted its holdings in Novartis AG (NYSE:NVS – Free Report) by 22.1% in the fourth quarter, according to its most recent 13F filing with the Securities ...
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer...
Benzinga· 4 days agoMorphoSys AG MOR is reportedly facing a burgeoning safety concern surrounding pelabresib, an...
News Highlights: Top Company News of the Day - Thursday at 9 AM ET
Morningstar· 19 hours agoShares ticked up premarket as the company says it plans to return $9 billion to shareholders through dividends and stock buybacks in 2024. For the first time since before the onset of the COVID ...
FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugs
The Wall Street Journal· 2 days agoAlso on the list are inhalers and more diabetes treatments from AstraZeneca Boehringer Ingelheim,...
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and...
WKBN 27 Youngstown· 2 days agoREGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March ...
CVS Caremark’s Policy Shift On Humira Biosimilars May Not Be What The Doctor Ordered
Forbes· 1 day agoAs of March, the blockbuster autoimmune drug Humira (adalimumab) still held 96% of the market share...
Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform to Discover Therapies...
KTLA-TV Los Angeles· 7 days agoThe company has raised $60 million to date from investors including The Longevity Fund, Arctica Ventures, Athos Service GmbH, Gigafund, Founders Fund, Fifty Years, and former Novartis ...
FTC targets ‘junk patents’ on Ozempic, other top drugs
BioPharma Dive via Yahoo Finance· 2 days agoThe move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate”...